Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial

被引:4
|
作者
Howard, Robert [1 ]
Cort, Elizabeth [1 ]
Rawlinson, Charlotte [1 ]
Wiegand, Martin [2 ]
Downey, Anne [2 ]
Lawrence, Vanessa [3 ]
Banerjee, Sube [4 ]
Bentham, Peter [5 ]
Fox, Chris [6 ]
Harwood, Rowan [7 ]
Hunter, Rachel [2 ]
Livingston, Gill [1 ]
Moniz-Cook, Esme [8 ]
Panca, Monica [2 ]
Raczek, Malgorzata [9 ]
Ivenso, Chineze [10 ]
Russell, Gregor [11 ]
Thomas, Alan [12 ]
Wilkinson, Philip [13 ]
Freemantle, Nicholas [14 ]
Gould, Rebecca [1 ]
机构
[1] UCL, Div Psychiat, London, England
[2] UCL, Priment Clin Trials Unit, London, England
[3] Kings Coll London, David Goldberg Ctr H1 01, London, England
[4] Univ Plymouth, Plymouth, Devon, England
[5] Birmingham & Solihull NHS Trust, Birmingham, England
[6] Univ East Anglia, Norwich, Norfolk, England
[7] Univ Nottingham, Queens Med Ctr, Nottingham, England
[8] Univ Hull, Kingston Upon Hull, England
[9] Brighton & Sussex Sch Med, Brighton, E Sussex, England
[10] Aneurin Bevan NHS Trust, St Cadocs Hosp, Newport, Wales
[11] Bradford Dist Care Fdn Trust, Bradford, England
[12] Univ Newcastle, Campus Ageing & Vital, Newcastle Upon Tyne, England
[13] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England
[14] UCL, Comprehens Clin Trials Unit, London, England
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; clinical trial; depression; mood; problem adaptation therapy; psychological; psychotherapy; MINI-MENTAL-STATE; ANXIETY; PEOPLE; SCALE;
D O I
10.1002/alz.13766
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
INTRODUCTION: Trials of effectiveness of treatment options for depression in dementia are an important priority. METHODS: Randomized controlled trial to assess adapted Problem Adaptation Therapy (PATH) for depression in mild/moderate dementia caused by Alzheimer's disease. RESULTS: Three hundred thirty-six participants with mild or moderate dementia, >7 on Cornell Scale for Depression in Dementia (CSDD), randomized to adapted PATH or treatment as usual. Mean age 77.0 years, 39.0% males, mean Mini-Mental State Examination 21.6, mean CSDD 12.9. For primary outcome (CSDD at 6 months), no statistically significant benefit with adapted PATH on the CSDD (6 months: -0.58; 95% CI -1.71 to 0.54). The CSDD at 3 months showed a small benefit with adapted PATH (-1.38; 95% CI -2.54 to -0.21) as did the EQ-5D (-4.97; 95% CI -9.46 to -0.48). DISCUSSION: An eight-session course of adapted PATH plus two booster sessions administered within NHS dementia services was not effective treatment for depression in people with mild and moderate dementia. Future studies should examine the effect of more intensive and longer-term therapy.
引用
收藏
页码:2990 / 2999
页数:10
相关论文
共 50 条
  • [31] Trial of solanezumab for mild dementia due to Alzheimer's disease
    Pickrell, William O.
    Robertson, Neil P.
    JOURNAL OF NEUROLOGY, 2018, 265 (09) : 2162 - 2162
  • [32] Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial
    Akhondzadeh, S.
    Shafiee-Sabet, M.
    Harirchian, M. H.
    Togha, M.
    Cheraghmakani, H.
    Razeghi, S.
    Hejazi, S. Sh
    Yousefi, M. H.
    Alimardani, R.
    Jamshidi, A.
    Zare, F.
    Moradi, A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (05) : 581 - 588
  • [33] Effects of Horticultural Activities on Mild to Moderate Depression Symptoms: A Randomized Controlled Trial
    Minagar, France
    Ahmadzad-Asl, Masoud
    Hashemi, Arash Tehrani Bani
    Tayefi, Batool
    Mohabbat, Nassim
    Ramezani, Mozhdeh
    IRANIAN JOURNAL OF PSYCHIATRY AND CLINICAL PSYCHOLOGY, 2023, 28 (04): : 412 - 429
  • [34] Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial
    Scheltens, Philip
    Twisk, Jos W. R.
    Blesa, Rafael
    Scarpini, Elio
    von Arnim, Christine A. F.
    Bongers, Anke
    Harrison, John
    Swinkels, Sophie H. N.
    Stam, Cornelis J.
    de Waal, Hanneke
    Wurtman, Richard J.
    Wieggers, Rico L.
    Vellas, Bruno
    Kamphuis, Patrick J. G. H.
    JOURNAL OF ALZHEIMERS DISEASE, 2012, 31 (01) : 225 - 236
  • [35] ABBY A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
    Cummings, Jeffrey L.
    Cohen, Sharon
    van Dyck, Christopher H.
    Brody, Mark
    Curtis, Craig
    Cho, William
    Ward, Michael
    Friesenhahn, Michel
    Rabe, Christina
    Brunstein, Flavia
    Quartino, Angelica
    Honigberg, Lee A.
    Fuji, Reina N.
    Clayton, David
    Mortensen, Deborah
    Ho, Carole
    Paul, Robert
    NEUROLOGY, 2018, 90 (21) : E1889 - E1897
  • [36] Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
    Piette, Francois
    Belmin, Joel
    Vincent, Helene
    Schmidt, Nicolas
    Pariel, Sylvie
    Verny, Marc
    Marquis, Caroline
    Mely, Jean
    Hugonot-Diener, Laurence
    Kinet, Jean-Pierre
    Dubreuil, Patrice
    Moussy, Alain
    Hermine, Olivier
    ALZHEIMERS RESEARCH & THERAPY, 2011, 3 (02)
  • [37] Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
    François Piette
    Joël Belmin
    Hélène Vincent
    Nicolas Schmidt
    Sylvie Pariel
    Marc Verny
    Caroline Marquis
    Jean Mely
    Laurence Hugonot-Diener
    Jean-Pierre Kinet
    Patrice Dubreuil
    Alain Moussy
    Olivier Hermine
    Alzheimer's Research & Therapy, 3
  • [38] Awareness of disease in dementia: preliminary results in patients with mild and moderate Alzheimer's disease
    Dourado, M
    Laks, J
    Rocha, M
    Soares, C
    Leibing, A
    Engelhardt, E
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2005, 63 (01) : 114 - 118
  • [39] Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy
    Modrego, P. J.
    Fayed, N.
    Errea, J. M.
    Rios, C.
    Pina, M. A.
    Sarasa, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (03) : 405 - 412
  • [40] Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial
    Dubois, Bruno
    Lopez-Arrieta, Jesus
    Lipschitz, Stanley
    Triantafyllos, Doskas
    Spiru, Luiza
    Moroz, Svitlana
    Venger, Olena
    Vermersch, Patrick
    Moussy, Alain
    Mansfield, Colin D. D.
    Hermine, Olivier
    Tsolaki, Magda
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)